

# Evidence-based clinical practice guidelines for gastroes

Journal of Gastroenterology

57, 267-285

DOI: [10.1007/s00535-022-01861-z](https://doi.org/10.1007/s00535-022-01861-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China. <i>Annals of Translational Medicine</i> , 2022, 10, 480-480.	1.7	5
2	Size reduction of gastric fundic gland polyposis by de-escalation of acid-suppressive therapy. <i>DEN Open</i> , 2023, 3, .	0.9	0
3	Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease. <i>Esophagus</i> , 2022, 19, 525-534.	1.9	11
4	Abordaje terapéutico de la enfermedad por reflujo gastroesofágico. <i>Acta Gastroenterologica Latinoamericana</i> , 2022, 52, 153-165.	0.1	0
5	Reply: Need for evidence on surveillance endoscopy in achalasia-related Barret esophagus and adenocarcinoma in Asian population. <i>Journal of Gastroenterology</i> , 0, , .	5.1	0
6	Local inflammatory response to gastroesophageal reflux: Association of gene expression of inflammatory cytokines with esophageal multichannel intraluminal impedance-pH data. <i>World Journal of Clinical Cases</i> , 2022, 10, 9254-9263.	0.8	2
7	Prevalence, Predictors, and Management of Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy: a Multicenter Cohort Study. <i>Obesity Surgery</i> , 2022, 32, 3541-3550.	2.1	7
8	Bridge Swallowing Exercise for Gastroesophageal Reflux Disease Symptoms: A Pilot Study. <i>Progress in Rehabilitation Medicine</i> , 2022, 7, n/a.	0.9	1
9	GERD-related chronic cough: Possible mechanism, diagnosis and treatment. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	4
10	Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	1
11	Study on syndrome rules of stagnated heat in liver and stomach of non-erosive reflux disease based on microecology of tongue coating. <i>Medicine (United States)</i> , 2022, 101, e31618.	1.0	0
12	Differences in salivary secretion and epidermal growth factor concentrations in mild reflux esophagitis and non-erosive reflux disease. <i>Esophagus</i> , 2023, 20, 317-324.	1.9	3
13	Bridge Swallowing Exercise for Stroke Patients with Gastroesophageal Reflux Disease Symptoms: A Case Series. <i>Progress in Rehabilitation Medicine</i> , 2022, 7, n/a.	0.9	0
14	Enfermedad por reflujo gastroesofágico. , 2022, 44, 328-337.		0
15	Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e31807.	1.0	4
16	The pathological conditions and surgical outcomes depending on the degree of hernia in the intra-thoracic stomach. <i>Esophagus</i> , 0, , .	1.9	0
17	Using deep learning and explainable artificial intelligence to assess the severity of gastroesophageal reflux disease according to the Los Angeles Classification System. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 596-604.	1.5	4
18	Esophageal Reflux Hypersensitivity: A Comprehensive Review. <i>Gut and Liver</i> , 2023, , .	2.9	0

#	ARTICLE	IF	CITATIONS
19	Ambulatory pH-Impedance Findings Confirm That Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 794-801.	0.4	11
20	Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 159-163.	0.8	1
22	Saliva Secretion Is Significantly Lower in Female Patients with Mild Reflux Esophagitis than in Female Healthy Controls. <i>Digestion</i> , 2023, 104, 299-305.	2.3	3
23	Development and Validation of Deep Learning Models for the Multiclassification of Reflux Esophagitis Based on the Los Angeles Classification. <i>Journal of Healthcare Engineering</i> , 2023, 2023, 1-8.	1.9	0
24	Heartburn relief with bicarbonate-rich mineral water: results of the randomised, placebo-controlled phase-III trial STOMACH STILL. <i>BMJ Open Gastroenterology</i> , 2023, 10, e001048.	2.7	3
26	Vonoprazan poses no additional risk of developing <i>Clostridioides difficile</i> infection compared to proton pump inhibitors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 940-947.	2.8	2
27	Chinese consensus on multidisciplinary diagnosis and treatment of gastroesophageal reflux disease 2022. , 2023, , .		0
28	Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311678.	3.2	3
29	JP1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases. <i>Pharmacology Research and Perspectives</i> , 2023, 11, .	2.4	2
30	Safety and efficacy of Roux-en-Y gastric bypass as revisional bariatric surgery after failed anti-reflux surgery: a systematic review. <i>Surgery for Obesity and Related Diseases</i> , 2023, 19, 1317-1325.	1.2	3
31	Prevalence of elderly eosinophilic esophagitis and their clinical characteristics. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 1222-1227.	1.5	0
32	Long-term efficacy of antireflux mucosectomy in patients with refractory gastroesophageal reflux disease. <i>Digestive Endoscopy</i> , 2024, 36, 305-313.	2.3	0
33	Significantly Lower Saliva Secretion in Females With Gastroesophageal Reflux Disease and Healthy Subjects Than in Males. <i>Cureus</i> , 2023, , .	0.5	0
34	The practical management of patients with gastroesophageal reflux: an Italian survey. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2023, 182, .	0.1	0
35	Competitive proton pump inhibitors - status and Prospects of use. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2023, , 86-92.	0.4	0
36	Endoscopic treatment of gastroesophageal reflux: a narrative review. <i>Porto Biomedical Journal</i> , 2023, 8, .	1.0	1
37	Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction. <i>Pharmaceuticals</i> , 2023, 16, 1213.	3.8	1
38	Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment. <i>Polymers</i> , 2023, 15, 3485.	4.5	4

#	ARTICLE	IF	CITATIONS
39	Among females older than 50 years, saliva secretion is significantly lower in non-erosive reflux disease patients than in healthy controls. <i>Esophagus</i> , 0, , .	1.9	0
40	Role of Potassium-competitive Acid Blockers in the Treatment of Gastric Acid-related Disorders. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2023, 23, 167-173.	0.4	0
41	History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2023, 23, 159-166.	0.4	1
42	Patients with gastroesophageal reflux disease (both reflux oesophagitis and non-erosive reflux) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Rehabilitation, 2024, 51, 305-312.	3.0	1
43	Proteomic analysis of stimulated saliva in gastroesophageal reflux disease patients with and without erosive tooth wear: Observational study. <i>Journal of Dentistry</i> , 2023, 139, 104724.	4.1	3
44	Real-world Prescription Patterns and Patient Satisfaction Regarding Maintenance Therapy of Gastroesophageal Reflux Disease: An Observational, Cross-sectional, Multicenter Study. <i>Journal of Neurogastroenterology and Motility</i> , 2023, 29, 470-477.	2.4	0
45	On-demand Versus Continuous Maintenance Treatment With a Proton Pump Inhibitor for Mild Gastroesophageal Reflux Disease: A Prospective Randomized Multicenter Study. <i>Journal of Neurogastroenterology and Motility</i> , 2023, 29, 460-469.	2.4	0
46	Modern aspects of managing patients with non-erosive reflux disease. <i>Meditinskiy Sovet</i> , 2023, , 28-33.	0.5	0
47	Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. <i>Pharmacotherapy</i> , 2024, 44, 171-183.	2.6	0
48	Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
49	Characteristics of proton pump inhibitor-resistant severe reflux esophagitis and efficacy of vonoprazan in elderly (older than 75 years) and non-elderly groups. <i>JGH Open</i> , 2024, 8, .	1.6	0
50	Chronic Use of Proton Pump Inhibitors: A Potential Link to Amino Acid Deficiency and the Development of Depression. <i>Cureus</i> , 2023, , .	0.5	0
51	PPI's efficacy in PCAB's, a 14%. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2023, 112, 7-9.	0.0	0
52	The Effect of Dexamprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1247.	4.1	0
53	Severe esophagitis induced by antituberculosis drugs: a case report. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 0, 66, .	1.1	0
54	Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
55	Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
56	Disproportionate cancer worries in ultra-short segment Barrett's esophagus in Japan. <i>DEN Open</i> , 2024, 4, .	0.9	0

#	ARTICLE	IF	CITATIONS
57	Heartburn and feeling full, even after a small meal. , 2024, , 409-414.		0
58	Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan. <i>Journal of Gastroenterology</i> , 2024, 59, 179-186.	5.1	0
59	Therapeutic Evaluation of <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> MH-02 as an Adjunctive Treatment in Patients with Reflux Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Nutrients</i> , 2024, 16, 342.	4.1	0
60	Pathomorphological criteria and features of immune response in eosinophilic esophagitis and reflux esophagitis. <i>Arkhiv Patologii</i> , 2024, 86, 5.	0.2	0
61	Tonghua Liyan granules in the treatment of Laryngopharyngeal reflux disease with stagnation of phlegm and qi syndrome: a randomized, double-blind, placebo-controlled study. <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
64	Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach. <i>Expert Review of Clinical Immunology</i> , 0, , 1-20.	3.0	0
65	Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer. <i>The Cochrane Library</i> , 2024, 2024, .	2.8	0
66	Effect of Laryngopharyngeal Reflux and Potassium-Competitive Acid Blocker (P-CAB) on the Microbiological Compose of the Laryngopharynx. <i>Otolaryngology - Head and Neck Surgery</i> , 2024, 170, 1380-1390.	1.9	0
68	Efficacy and safety of endoscopic cardia peripheral tissue scar formation (ECSF) for the treatment of refractory gastroesophageal reflux disease: A systematic review with meta-analysis. <i>Medicine (United Tj ETQq0 0 OrgBT /Overlock 10 T</i>		
69	A Meta-analysis of PPIs Plus Alginate Versus PPIs Alone for the Treatment of GERD. <i>Journal of Voice</i> , 2024, , .	1.5	0
70	A systematic review with meta-analysis: Efficacy and safety of <scp>potassium-competitive</scp> acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. <i>JGH Open</i> , 2024, 8, .	1.6	0
71	Gastroesophageal reflux disease, obesity, bronchial asthma: simple combination or complex interaction. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2024, , 77-87.	0.4	0
72	Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor: A Pilot Study on Comparable Efficacy in the Treatment of Gastroesophageal Reflux-Related Cough. <i>Allergy, Asthma and Immunology Research</i> , 2024, 16, 191.	2.9	0